ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $179.21M |
| Expense Ratio | 0.50% |
| PE Ratio | 6.51 |
| Forward PE | 21.45 |
| Shares Out | 3.48M |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 35,751 |
| Open | 51.90 |
| Previous Close | 51.20 |
| Day's Range | 51.89 - 52.13 |
| 52-Week Low | 41.22 |
| 52-Week High | 70.85 |
| Beta | 0.77 |
| Holdings | 104 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
31.14% of assets| Name | Symbol | Weight |
|---|---|---|
| CG Oncology, Inc. | CGON | 3.92% |
| Oruka Therapeutics, Inc. | ORKA | 3.63% |
| Travere Therapeutics, Inc. | TVTX | 3.59% |
| Veradermics, Incorporated | MANE | 3.39% |
| Definium Therapeutics, Inc. | DFTX | 3.29% |
| Dianthus Therapeutics, Inc. | DNTH | 2.99% |
| Edgewise Therapeutics, Inc. | EWTX | 2.87% |
| Relay Therapeutics, Inc. | RLAY | 2.67% |
| Amylyx Pharmaceuticals, Inc. | AMLX | 2.42% |
| Acadia Pharmaceuticals Inc. | ACAD | 2.37% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.17346 | Dec 26, 2024 |
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
Performance
SBIO had a total return of 27.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.11%.
News
Biotech ETF SBIO Can Get Its Groove Back
With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction...
SBIO ETF Rallies on Clinical Trial Wins & M&A Demand
The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside. SBIO posted a solid 5% gain...
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record
The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing ...
CREATOR TV SPORTS™ UNVEILS CREATOR LINEUP FOR INAUGURAL "CREATOR PICKLEBALL TOUR" AT VIDCON ANAHEIM
NichLmao, Peet Montzingo, DangMattSmith, Merrick Hanna and more to compete in a 16-player tournament produced by Creator TV®, set to premiere on streaming this summer. LOS ANGELES, June 15, 2026 /PRNe...
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...